Obagi Medical and Waldencast plc completed an acquisition expanding into dermal fillers and granting US rights to the Saypha line, while Trump-era tariffs benefit AI stocks.
1 report, 1 independent
Updated Aug 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Obagi Medical and Waldencast plc completed an acquisition expanding into dermal fillers and granting US rights to the Saypha line, while Trump-era tariffs benefit AI stocks.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Corporate activity in the medical device sector in August 2025 included M&A activity (Stryker/Inari Medical, ZimVie/Archimed), competition between Medtronic and Intuitive Surgical, and the impact of Trump administration tariffs and FDA reviews.Also in this story
- FDA approved Medtronic's Hugo robotic system for urological procedures, marking a major competitive shift in the medical device sector.
- Market sentiment regarding growth rates turned disappointing for companies like Profound Medical on August 1, 2025.
- Medtronic is developing a robotic-assisted surgery system that needs regulatory approval in the US, amidst aggressive trade policy threats.
- Lemaitre, Intuitive Surgical, and Teleflex are identified as companies operating in the surgical equipment segment.
The entities involved
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Coverage
Newest first; wire copies grouped- Insider MonkeyWaldencast plc (WALD) Acquired Novaestiq Corp. and the US Rights to the Saypha Line of Hyaluronic Acid Injectable Gels Waldencast plc (NASDAQ:WALD) is one of the Best 52-Week Low Penny Stocks to Buy